Good things come to those who wait, but we’re an impatient bunch here at Nanalyze. It’s no wonder that we decided to write about disruptive technology rather than spend the time actually creating it. Consider that it took an international team of scientists 13 years and $3 billion to map the genes that comprise the […]
Fewer than half of Americans own a passport. Some say that’s because their own backyard is such a big one. The half of our audience that hails from there may not be aware of what’s happening with global travel because they’re blissfully watching the stock market soar inexplicably. According to the World Tourism Barometer, international […]
If you are lucky enough to have spent upwards of six figures on your MBA, you may be tempted to think that it was a waste of money now that the robots are in the process of devouring just about every job there is. That’s just not the case though. MBAs happen to be equipped with some very […]
We’ve had boots on the ground in China for some time now, and we’re firmly convinced that investment exposure to China is a must. A recent article by Peter Diamandis on the topic pointed out the 9-9-6 work culture for Chinese startups which stands for 9 AM to 9 PM, 6 days a week – […]
The concept of personalized medicine—using the latest and greatest genetic tests and related technologies—might seem like it was born out of a Silicon Valley think tank. But, in reality, the idea goes back thousands of years. Ayurvedic medicine, practiced in some form by nearly all of India’s 1.3 billion people, is probably the most well-known […]
The Chinese are some of the most fascinating people on the planet as far as we’re concerned, all 1.379 billion of them. They mastered medicine long before the West did, they love to ride bikes, they have some of the best and most widely varied Chinese food of any country out there, they love to speak […]
Illumina stock (NASDAQ:ILMN) represents a picks and shovels play on some of the most exciting disruptive technologies we discuss here on Nanalyze like genetic testing, synthetic biology, gene editing, and pretty much each and every technology theme that involves analyzing genes. That isn’t even the most compelling reason to want to invest in Illumina. We’ve talked before about their […]
Illumina (NASDAQ:ILMN) sequencing machines have opened the door for genomics unlike any other company today. Investors who bought shares of ILMN 10 years ago would have enjoyed a share price appreciation so far of over +1100%. With the stock price down -37% from their all-time high of $242 per share seen in mid-2015, it may make […]